NAV 1003
12 Apr 2022
Trial Summary
A Phase 1 Study of the SHP2 Inhibitor BBP-398 (formerly known as IACS-15509) in combination with the KRAS-G12C Inhibitor Sotorasib in Patients with Advanced Solid Tumors and a KRASG12C Mutation
Acronym:
NAV 1003
ACTRN/NCT /ethics:
–
Scientific title:
–
Sponsor / Cooperative group:
–
Trial & Patient Characteristics
| Cancer Type | All cancers |
|---|---|
| Trial Type | Treatment |
| Phase | Phase I |
| Age Range | - |
| Sex | - |
| Tumour Stream | - |
| Cancer Stage | Locally Recurrent or Locally Advanced; Metastatic or Widespread |
| Anticipated Start Date | - |
| Anticipated End Date | - |
Participating Hospitals
| Hospital | Cancer Research SA |
|---|---|
| Clinical Trial Coordinator | Kelly Mead |
| admin@cancerresearchsa.com.au | |
| Phone | 08 8359 2565 |
| Principal Investigator | A/Prof Rohit Joshi |
| Recruitment Status | Recruiting |